Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call today at 10:00 a.m. ET UNIONDALE, NY, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase") and Advanced Biological Laboratories S.A. ("ABL"), a European biotechnology and MedTech group, today announced that they have entered into a non-binding Letter of Intent ("LOI") regarding a propos ...

Class A Ordinary Shares Will Begin Trading on a Post-Consolidation Adjusted Basis onDecember 23, 2025 BEIJING, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding,” “we” or the “Company”), a leading provider of next-generation mobile internet infrastructure and platform services, today announced that it intends to effect a share consolidation of its ordinary shares at a ratio of 1 post-split Class A ordinary share for every 50 pre-split ordinary shares (the “Share Consolidati ...

-- Quarterly Net Revenues Increase 12.3%, Driven by Growth in Motorhome and Towable RV Segments -- -- Improved Top-Line Performance and Cost Discipline Deliver Margin Gains and Strengthen Balance Sheet -- -- Barletta Continues Share Expansion in U.S. Aluminum Pontoon Segment(1) -- -- Motorized Offerings from Newmar and Grand Design Fuel Share Growth in Class A and Class C(1) -- -- Company Raises FY 2026 Earnings Guidance Range -- EDEN PRAIRIE, Minn., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Winnebago Industri ...

MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed t ...

12:00 London, 14:00 Helsinki, 19 December 2025 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR) AFARAK GROUP SE´S 2026 FINANCIAL REPORTING CALENDAR Stock Exchange Release Afarak Group SE ("Afarak" or the "Company") will publish its financial results as follows: - Full Year 2025 Results on Friday 27 February 2026 - Annual Report 2025 during the week commencing 23 March 2026 - Report for six months ending 30 June on Friday 14 August 2026 The Company's Annual General Meeting is schedule ...

Core Viewpoint - Albion Technology & General VCT PLC has successfully allotted 19,195,552 ordinary shares as part of its subscription offer for the 2025/26 tax year, raising approximately £13.2 million in net proceeds [2][4]. Group 1: Share Allotment Details - The company allotted 3,570,012 Offer Shares to existing shareholders at an issue price of 70.41 pence per share and 670,420 Offer Shares to new subscribers at 70.77 pence per share, both qualifying for early bird discounts [4]. - An additional 14,955,120 Offer Shares were allotted at an issue price of 71.14 pence per share, which did not qualify for early bird discounts [4]. - The total amount raised across the Albion VCTs under the Offers is £44 million as of 19 December 2025 [6]. Group 2: Early Bird Discounts and Pricing Structure - The company offered a 1% early bird discount on issue costs to existing shareholders and a 0.5% discount to new subscribers for the first £10 million of subscriptions [3]. - The pricing structure of the Offer Shares was designed to prevent capital dilution for existing shareholders who did not participate in the Offers [3]. Group 3: Regulatory and Trading Information - Application has been made to the Financial Conduct Authority for the admission of the Offer Shares to the Official List and for trading on the London Stock Exchange, expected to commence around 22 December 2025 [5]. - As of 19 December 2025, the company's total issued share capital consists of 427,887,766 ordinary shares, with 32,370,947 shares held in treasury [6]. - The total number of voting rights in the company is 395,516,819, which shareholders can use for interest notifications under the FCA's Disclosure Guidance and Transparency Rules [7].

Core Viewpoint - Premier Development & Investment, Inc. is enhancing its Investor Relations and online presence to better communicate its business developments and engage with investors [2][5]. Group 1: Investor Relations and Communication - The company is heavily investing in Investor Relations and exposure to ensure accurate understanding and scrutiny of its operations [2]. - A comprehensive website is under construction, aimed at providing extensive information about the company and its mining reports [4][5]. - The company encourages stockholders and interested parties to sign up on its website and follow its social media for real-time updates on Press Releases, Financial Reports, and other important information [6]. Group 2: Business Operations - Premier is focused on Lithium and Uranium exploration in Nevada, covering approximately 3,800 acres, and has Rare Earth Exploration properties in New Mexico [9]. - The company holds options over Oil & Gas Wells in Oklahoma and is increasing its stake in GNCC Capital, Inc. from 31% to 49% by December 2025 [9].

Core Insights - Parsons Corporation has been awarded a task order exceeding $100 million by Nammo to manage the design and construction of a new rocket motor manufacturing facility in Perry, Florida, which supports the Department of War's acquisition strategy [1][2] - The project aims to enhance the U.S. munitions production capacity, improve supply chain resilience, and expedite the delivery of critical capabilities to military personnel [1][2] Company Overview - Parsons is recognized as a leading provider in national security and global infrastructure markets, specializing in areas such as cyber and electronic warfare, space and missile defense, and critical infrastructure protection [5] - The company has been ranked as the world's top program management and a leading construction management firm by Engineering News-Record in 2025 [2] Project Details - The contract includes a two-year construction period and represents new work for Parsons, marking a significant step in expanding the U.S. munitions industrial base [1][2] - The Perry site serves as a center of excellence for munitions and pyrotechnic products, providing energetic systems to the Department of War [2] Industry Context - Nammo, the partner in this project, is an international aerospace and defense company with over 4,000 employees and 27 production sites, recognized for its specialty ammunition and rocket motors [4]

Core Insights - Altimmune, Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks [2][3] Group 1: Trial Results - Statistically significant improvements in key non-invasive markers of fibrosis, including Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), were observed across treatment arms compared to placebo [3][5] - The 1.2 mg and 1.8 mg doses of pemvidutide achieved mean reductions in ELF of -0.49 and -0.58 respectively, versus +0.16 in placebo (p<0.0001) [5] - The 1.2 mg and 1.8 mg doses achieved mean reductions in LSM of -3.04 (p<0.05) and -3.97 (p<0.001) respectively, compared to -0.03 in placebo [5] - Participants receiving pemvidutide also showed significant reductions in liver fat content, alanine aminotransferase (ALT), and corrected T1 (cT1) [5] - Weight loss was observed with the 1.2 mg and 1.8 mg doses at 4.5% and 7.5% respectively, compared to 0.2% in placebo (p<0.0001) [13] Group 2: Tolerability and Safety - The tolerability profile of pemvidutide was favorable at 48 weeks, with low treatment-related discontinuation rates of 0% and 1.2% for the 1.2 mg and 1.8 mg doses respectively, compared to 3.5% for placebo [13] - No serious or severe adverse events related to treatment were reported [13] Group 3: Regulatory Progress - The company held a productive End-of-Phase 2 meeting with the FDA, aligning on parameters for a registrational Phase 3 trial for pemvidutide in MASH patients with moderate to advanced liver fibrosis [6][7] - The FDA's qualification of AIM-MASH AI Assist was noted, which aims to standardize histologic assessment in the Phase 3 trial [6] Group 4: Future Plans - The company plans to initiate the Phase 3 program for pemvidutide in 2026, leveraging the strong evidence of antifibrotic improvements and favorable tolerability [7]

Core Insights - Subsea 7 S.A. has received a significant extension of an existing frame agreement from Equinor for subsea inspection, maintenance, and repair services for the vessel Seven Viking, which will last until the end of 2027 [1][2] - The extension allows Seven Viking to perform IMR services for Equinor's oil and gas wells located on the Norwegian Continental Shelf, with project management and engineering work continuing from Subsea 7's Stavanger office [2][3] - Erik Femsteinevik, VP of Subsea 7 Norway, expressed appreciation for Equinor's decision to extend the IMR contract, emphasizing the commitment to support safe and efficient operations [3] Company Overview - Subsea 7 is recognized as a global leader in delivering offshore projects and services, focusing on creating sustainable value and being a preferred partner in the energy industry [3]